vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Boxlight Corp (BOXL). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $29.3M, roughly 1.5× Boxlight Corp). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -21.1%, a 1.1% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -19.2%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -23.1%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Boxlight Corp is a global provider of interactive technology solutions, including interactive flat panel displays, projectors, collaborative software, and classroom technology accessories. It primarily serves K-12 and higher education institutions, as well as corporate and government customers across North America, Europe, and Asia Pacific, focusing on enhancing learning and work collaboration efficiency.

ABCL vs BOXL — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.5× larger
ABCL
$44.9M
$29.3M
BOXL
Growing faster (revenue YoY)
ABCL
ABCL
+807.5% gap
ABCL
788.4%
-19.2%
BOXL
Higher net margin
ABCL
ABCL
1.1% more per $
ABCL
-19.9%
-21.1%
BOXL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
-23.1%
BOXL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ABCL
ABCL
BOXL
BOXL
Revenue
$44.9M
$29.3M
Net Profit
$-8.9M
$-6.2M
Gross Margin
29.1%
Operating Margin
-63.7%
-13.4%
Net Margin
-19.9%
-21.1%
Revenue YoY
788.4%
-19.2%
Net Profit YoY
73.9%
-102.0%
EPS (diluted)
$-0.03
$-1.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
BOXL
BOXL
Q4 25
$44.9M
Q3 25
$9.0M
$29.3M
Q2 25
$17.1M
$30.9M
Q1 25
$4.2M
Q4 24
$5.0M
$24.0M
Q3 24
$6.5M
$36.3M
Q2 24
$7.3M
$38.5M
Q1 24
$10.0M
$37.1M
Net Profit
ABCL
ABCL
BOXL
BOXL
Q4 25
$-8.9M
Q3 25
$-57.1M
$-6.2M
Q2 25
$-34.7M
$-4.7M
Q1 25
$-45.6M
Q4 24
$-16.7M
Q3 24
$-51.1M
$-3.1M
Q2 24
$-36.9M
$-1.5M
Q1 24
$-40.6M
$-7.1M
Gross Margin
ABCL
ABCL
BOXL
BOXL
Q4 25
Q3 25
29.1%
Q2 25
35.0%
Q1 25
Q4 24
30.6%
Q3 24
33.8%
Q2 24
37.7%
Q1 24
34.5%
Operating Margin
ABCL
ABCL
BOXL
BOXL
Q4 25
-63.7%
Q3 25
-851.8%
-13.4%
Q2 25
-290.2%
-12.7%
Q1 25
-1479.6%
Q4 24
-67.6%
Q3 24
-1439.4%
-2.4%
Q2 24
-1276.2%
3.2%
Q1 24
-551.5%
-9.7%
Net Margin
ABCL
ABCL
BOXL
BOXL
Q4 25
-19.9%
Q3 25
-637.8%
-21.1%
Q2 25
-203.3%
-15.3%
Q1 25
-1077.2%
Q4 24
-69.6%
Q3 24
-785.4%
-8.4%
Q2 24
-504.3%
-3.8%
Q1 24
-408.0%
-19.1%
EPS (diluted)
ABCL
ABCL
BOXL
BOXL
Q4 25
$-0.03
Q3 25
$-0.19
$-1.88
Q2 25
$-0.12
$-1.53
Q1 25
$-0.15
Q4 24
$-87.29
Q3 24
$-0.17
$-1.72
Q2 24
$-0.13
$-0.92
Q1 24
$-0.14
$-0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
BOXL
BOXL
Cash + ST InvestmentsLiquidity on hand
$128.5M
$11.8M
Total DebtLower is stronger
$36.7M
Stockholders' EquityBook value
$966.9M
$-19.5M
Total Assets
$1.4B
$99.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
BOXL
BOXL
Q4 25
$128.5M
Q3 25
$83.2M
$11.8M
Q2 25
$92.4M
$7.6M
Q1 25
$159.3M
Q4 24
$156.3M
$8.0M
Q3 24
$126.6M
$10.5M
Q2 24
$148.3M
$7.5M
Q1 24
$123.6M
$11.8M
Total Debt
ABCL
ABCL
BOXL
BOXL
Q4 25
Q3 25
$36.7M
Q2 25
$39.0M
Q1 25
Q4 24
$37.1M
Q3 24
$38.8M
Q2 24
$40.3M
Q1 24
$38.5M
Stockholders' Equity
ABCL
ABCL
BOXL
BOXL
Q4 25
$966.9M
Q3 25
$964.0M
$-19.5M
Q2 25
$1.0B
$-20.6M
Q1 25
$1.0B
Q4 24
$1.1B
$-12.9M
Q3 24
$1.1B
$6.5M
Q2 24
$1.1B
$7.5M
Q1 24
$1.1B
$9.1M
Total Assets
ABCL
ABCL
BOXL
BOXL
Q4 25
$1.4B
Q3 25
$1.4B
$99.6M
Q2 25
$1.4B
$99.2M
Q1 25
$1.3B
Q4 24
$1.4B
$115.3M
Q3 24
$1.4B
$142.9M
Q2 24
$1.4B
$141.3M
Q1 24
$1.5B
$142.4M
Debt / Equity
ABCL
ABCL
BOXL
BOXL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
5.93×
Q2 24
5.38×
Q1 24
4.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
BOXL
BOXL
Operating Cash FlowLast quarter
$-34.7M
$1.3M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
BOXL
BOXL
Q4 25
$-34.7M
Q3 25
$-52.6M
$1.3M
Q2 25
$-32.4M
Q1 25
$-11.6M
Q4 24
$-108.6M
$1.6M
Q3 24
$-28.9M
$5.2M
Q2 24
$-30.0M
$-5.4M
Q1 24
$-41.7M
$-1.9M
Free Cash Flow
ABCL
ABCL
BOXL
BOXL
Q4 25
$-44.6M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
Q4 24
$-187.0M
Q3 24
$-47.4M
Q2 24
$-50.1M
Q1 24
$-65.8M
FCF Margin
ABCL
ABCL
BOXL
BOXL
Q4 25
-99.4%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
Q4 24
-3702.8%
Q3 24
-728.4%
Q2 24
-683.8%
Q1 24
-661.5%
Capex Intensity
ABCL
ABCL
BOXL
BOXL
Q4 25
21.9%
Q3 25
99.7%
Q2 25
78.2%
Q1 25
251.1%
Q4 24
1552.7%
Q3 24
284.6%
Q2 24
274.6%
Q1 24
242.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

BOXL
BOXL

Products$27.4M93%
Services$2.0M7%

Related Comparisons